Juno Therapeutics (JUNO) Tops Q3 EPS by 6c

Juno Therapeutics (NASDAQ: JUNO) reported Q3 EPS of ($0.73), $0.06 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $16.03 million.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• iQIYI (IQ) Misses Q2 EPS by 21c